Treatment of naive patients with chronic hepatitis C

This publication has 17 references indexed in Scilit:

• Interferon alfa for chronic hepatitis C infection
  The Lancet, 1999
• Influence of Pre-treatment Factors on Outcome of Interferon-alpha Treatment of Patients with Chronic Hepatitis C
  Scandinavian Journal of Infectious Diseases, 1999
• Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
  New England Journal of Medicine, 1998
• Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C
  New England Journal of Medicine, 1998
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
  Published by Elsevier ,1998
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
  Science, 1998
• The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses.
  Journal of General Virology, 1998
• Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
  The Lancet, 1998
• Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers
  Journal of Hepatology, 1997
• Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
  Gastroenterology, 1996